Loss of BMI-1 expression is associated with clinical progress of malignant melanoma
- PMID: 18246051
- DOI: 10.1038/modpathol.2008.17
Loss of BMI-1 expression is associated with clinical progress of malignant melanoma
Abstract
BMI-1 is a member of the Polycomb group of genes (PcGs) and is involved in embryonic gene regulation and maintenance of adult stem cells. It has been suggested that BMI-1 protein is important in cell cycle regulation, since both p16/INK4a and p14/ARF are downstream BMI-1 targets. BMI-1 has been implicated in the development and progression of several malignancies, but its role in melanocytic tumors of the skin is unknown. In the present study, using immunohistochemistry on 178 benign and malignant melanocytic lesions and two different antibodies, BMI-1 expression was reduced in melanomas compared with benign nevi. In established melanomas, loss of BMI-1 expression was associated with features of aggressive tumors, such as increased tumor cell proliferation, presence of necrosis and increased expression of both N-cadherin and beta3-integrin, indicating a more invasive and mesenchymal phenotype. Low BMI-1 expression was associated with low p14 and CDK4 but not with p16 expression. Low levels of BMI-1 expression were also significantly associated with decreased patient survival.
Similar articles
-
Consistent expression of the stem cell renewal factor BMI-1 in primary and metastatic melanoma.Int J Cancer. 2007 Oct 15;121(8):1764-70. doi: 10.1002/ijc.22891. Int J Cancer. 2007. PMID: 17597110
-
Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma.Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8606-14. doi: 10.1158/1078-0432.CCR-05-0011. Clin Cancer Res. 2005. PMID: 16361544
-
Stem cell protein BMI-1 is an independent marker for poor prognosis in oligodendroglial tumours.Neuropathol Appl Neurobiol. 2008 Oct;34(5):555-63. doi: 10.1111/j.1365-2990.2008.00949.x. Epub 2008 Mar 10. Neuropathol Appl Neurobiol. 2008. PMID: 18346113
-
Expression of polycomb group protein EZH2 in nevi and melanoma.J Cutan Pathol. 2007 Aug;34(8):597-600. doi: 10.1111/j.1600-0560.2006.00678.x. J Cutan Pathol. 2007. PMID: 17640228
-
Cytoskeleton alterations in melanoma: aberrant expression of cortactin, an actin-binding adapter protein, correlates with melanocytic tumor progression.Mod Pathol. 2010 Feb;23(2):187-96. doi: 10.1038/modpathol.2009.157. Epub 2009 Nov 6. Mod Pathol. 2010. PMID: 19898426 Free PMC article.
Cited by
-
The Clinical Relevance of Epithelial-to-Mesenchymal Transition Hallmarks: A Cut-Off-Based Approach in Healthy and Cancerous Cell Lines.Int J Mol Sci. 2025 Apr 11;26(8):3617. doi: 10.3390/ijms26083617. Int J Mol Sci. 2025. PMID: 40332096 Free PMC article.
-
SSX2 is a novel DNA-binding protein that antagonizes polycomb group body formation and gene repression.Nucleic Acids Res. 2014 Oct;42(18):11433-46. doi: 10.1093/nar/gku852. Epub 2014 Sep 23. Nucleic Acids Res. 2014. PMID: 25249625 Free PMC article.
-
BMI1 induces an invasive signature in melanoma that promotes metastasis and chemoresistance.Genes Dev. 2016 Jan 1;30(1):18-33. doi: 10.1101/gad.267757.115. Epub 2015 Dec 17. Genes Dev. 2016. PMID: 26679841 Free PMC article.
-
Bmi-1 serves as a potential novel marker for progression in human cutaneous basal cell carcinoma.Int J Clin Exp Pathol. 2017 Aug 1;10(8):8928-8935. eCollection 2017. Int J Clin Exp Pathol. 2017. PMID: 31966762 Free PMC article.
-
Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications.Med Res Rev. 2015 Nov;35(6):1220-67. doi: 10.1002/med.21358. Epub 2015 Jul 30. Med Res Rev. 2015. PMID: 26227500 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials